PSMC1 explained

26S protease regulatory subunit 4, also known as 26S proteasome AAA-ATPase subunit Rpt2, is an enzyme that in humans is encoded by the PSMC1 gene.^{[1] [2]} This protein is one of the 19 essential subunits of a complete assembled 19S proteasome complex.^[3] Six 26S proteasome AAA-ATPase subunits (Rpt1, Rpt2 (this protein), Rpt3, Rpt4, Rpt5, and Rpt6) together with four non-ATPase subunits (Rpn1, Rpn2, Rpn10, and Rpn13) form the base sub complex of 19S regulatory particle for proteasome complex.^[3]

Gene

The gene PSMC1 encodes one of the ATPase subunits, a member of the triple-A family of ATPases which have a chaperone-like activity. The human PSMC1 gene has 11 exons and locates at chromosome band 14q32.11.

Protein

The human protein 26S protease regulatory subunit 4 is 49kDa in size and composed of 440 amino acids. The calculated theoretical pI of this protein is 526S protease regulatory subunit 5.68. One expression isoform is generated by alternative splicing, in which 1-73 of the amino acid sequence is missing.^[4]

Complex assembly

26S proteasome complex is usually consisted of a 20S core particle (CP, or 20S proteasome) and one or two 19S regulatory particles (RP, or 19S proteasome) on either one side or both side of the barrel-shaped 20S. The CP and RPs pertain distinct structural characteristics and biological functions. In brief, 20S sub complex presents three types proteolytic activities, including caspase-like, trypsin-like, and chymotrypsin-like activities. These proteolytic active sites located in the inner side of a chamber formed by 4 stacked rings of 20S subunits, preventing random protein-enzyme encounter and uncontrolled protein degradation. The 19S regulatory particles can recognize ubiquitin-labeled protein as degradation substrate, unfold the protein to linear, open the gate of 20S core particle, and guide the substrate into the proteolytic chamber. To meet such functional complexity, 19S regulatory particle contains at least 18 constitutive subunits. These subunits can be categorized into two classes based on the ATP dependence of subunits, ATP-dependent subunits and ATP-independent subunits. According to the protein interaction and topological characteristics of this multisubunit complex, the 19S regulatory particle is composed of a base and a lid subcomplex. The base consists of a ring of six AAA ATPases (Subunit Rpt1-6, systematic nomenclature) and four non-ATPase subunits (Rpn1, Rpn2, Rpn10, and Rpn13). Thus, 26S protease regulatory subunit 4 (Rpt2) is an essential component of forming the base subcomplex of 19S regulatory particle. For the assembly of 19S base sub complex, four sets of pivotal assembly chaperons (Hsm3/S5b, Nas2/P27, Nas6/P28, and Rpn14/PAAF1, nomenclature in yeast/mammals) were identified by four groups independently.^{[5] [6] [7] [8] [9] [10]} These 19S regulatory particle base-dedicated chaperons all binds to individual ATPase subunits through the C-terminal regions. For example, Hsm3/S5b binds to the subunit Rpt1 and Rpt2 (this protein), Nas2/p27 to Rpt5, Nas6/p28 to Rpt3, and Rpn14/PAAAF1 to Rpt6, respectively. Subsequently, three intermediate assembly modules are formed as following, the Nas6/p28-Rpt3-Rpt6-Rpn14/PAAF1 module, the Nas2/p27-Rpt4-Rpt5 module, and the Hsm3/S5b-Rpt1-Rpt2-Rpn2 module. Eventually, these three modules assemble together to form the heterohexameric ring of 6 Atlases with Rpn1. The final addition of Rpn13 indicates the completion of 19S base sub complex assembly.^[3]

Function

As the degradation machinery that is responsible for ~70% of intracellular proteolysis,^[11] proteasome complex (26S proteasome) plays a critical roles in maintaining the homeostasis of cellular proteome. Accordingly, misfolded proteins and damaged protein need to be continuously removed to recycle amino acids for new synthesis; in parallel, some key regulatory proteins fulfill their biological functions via selective degradation; furthermore, proteins are digested into peptides for MHC class I antigen presentation. To meet such complicated demands in biological process via spatial and temporal proteolysis, protein substrates have to be recognized, recruited, and eventually hydrolyzed in a well controlled fashion. Thus, 19S regulatory particle pertains a series of important capabilities to address these functional challenges. To recognize protein as designated substrate, 19S complex has subunits that are capable to recognize proteins with a special degradative tag, the ubiquitinylation. It also have subunits that can bind with nucleotides (e.g., ATPs) in order to facilitate the association between 19S and 20S particles, as well as to cause confirmation changes of alpha subunit C-terminals that form the substrate entrance of 20S complex.

The ATPases subunits assemble into a six-membered ring with a sequence of Rpt1–Rpt5–Rpt4–Rpt3–Rpt6–Rpt2, which interacts with the seven-membered alpha ring of 20S core particle and establishes an asymmetric interface between the 19S RP and the 20S CP.^{[12] [13]} Three C-terminal tails with HbYX motifs of distinct Rpt ATPases insert into pockets between two defined alpha subunits of the CP and regulate the gate opening of the central channels in the CP alpha ring.^{[14] [15]}

Clinical significance

The proteasome and its subunits are of clinical significance for at least two reasons: (1) a compromised complex assembly or a dysfunctional proteasome can be associated with the underlying pathophysiology of specific diseases, and (2) they can be exploited as drug targets for therapeutic interventions. More recently, more effort has been made to consider the proteasome for the development of novel diagnostic markers and strategies. An improved and comprehensive understanding of the pathophysiology of the proteasome should lead to clinical applications in the future.

The proteasomes form a pivotal component for the ubiquitin–proteasome system (UPS) ^[16] and corresponding cellular Protein Quality Control (PQC). Protein ubiquitination and subsequent proteolysis and degradation by the proteasome are important mechanisms in the regulation of the cell cycle, cell growth and differentiation, gene transcription, signal transduction and apoptosis.^[17] Subsequently, a compromised proteasome complex assembly and function lead to reduced proteolytic activities and the accumulation of damaged or misfolded protein species. Such protein accumulation may contribute to the pathogenesis and phenotypic characteristics in neurodegenerative diseases,^{[18] [19]} cardiovascular diseases,^{[20] [21] [22]} inflammatory responses and autoimmune diseases,^[23] and systemic DNA damage responses leading to malignancies.^[24]

Several experimental and clinical studies have indicated that aberrations and deregulations of the UPS contribute to the pathogenesis of several neurodegenerative and myodegenerative disorders, including Alzheimer's disease,^[25] Parkinson's disease^[26] and Pick's disease,^[27] Amyotrophic lateral sclerosis (ALS),^[27] Huntington's disease,^[26] Creutzfeldt–Jakob disease,^[28] and motor neuron diseases, polyglutamine (PolyQ) diseases, Muscular dystrophies^[29] and several rare forms of neurodegenerative diseases associated with dementia.^[30] As part of the ubiquitin–proteasome system (UPS), the proteasome maintains cardiac protein homeostasis and thus plays a significant role in cardiac ischemic injury,^[31] ventricular hypertrophy^[32] and heart failure.^[33] Additionally, evidence is accumulating that the UPS plays an essential role in malignant transformation. UPS proteolysis plays a major role in responses of cancer cells to stimulatory signals that are critical for the development of cancer. Accordingly, gene expression by degradation of transcription factors, such as p53, c-jun, c-Fos, NF-κB, c-Myc, HIF-1α, MATα2, STAT3, sterol-regulated element-binding proteins and androgen receptors are all controlled by the UPS and thus involved in the development of various malignancies.^[34] Moreover, the UPS regulates the degradation of tumor suppressor gene products such as adenomatous polyposis coli (APC) in colorectal cancer, retinoblastoma (Rb). and von Hippel–Lindau tumor suppressor (VHL), as well as a number of proto-oncogenes (Raf, Myc, Myb, Rel, Src, Mos, ABL). The UPS is also involved in the regulation of inflammatory responses. This activity is usually attributed to the role of proteasomes in the activation of NF-κB which further regulates the expression of pro inflammatory cytokines such as TNF-α, IL-β, IL-8, adhesion molecules (ICAM-1, VCAM-1, P-selectin) and prostaglandins and nitric oxide (NO).^[23] Additionally, the UPS also plays a role in inflammatory responses as regulators of leukocyte proliferation, mainly through proteolysis of cyclines and the degradation of CDK inhibitors.^[35] Lastly, autoimmune disease patients with SLE, Sjögren syndrome and rheumatoid arthritis (RA) predominantly exhibit circulating proteasomes which can be applied as clinical biomarkers.^[36]

In humans the 26S protease regulatory subunit 4', also known as 26S proteasome AAA-ATPase subunit Rpt2, is an enzyme that is encoded by the PSMC1 gene.^{[1] [2]} This protein and is one of the 19 essential subunits of a complete assembled 19S proteasome complex.^[3] Megakaryocytes that were isolated from mice deficient for PSMC1 failed to produce pro platelets. The failure to produce proplatelets in proteasome-inhibited megakaryocytes was due to upregulation and hyperactivation of the small GTPase, RhoA. It appears that proteasome function, through an underlying mechanisms involving PSMC1, is critical for thrombopoiesis. Furthermore, inhibition of RhoA signaling in this process may be a potential strategy to treat thrombocytopenia in bortezomib-treated multiple myeloma patients.^[37]

Interactions

PSMC1 has been shown to interact with PSMD2^{[38] [39]} and PSMC2.^{[39] [40]}

Further reading

• Coux O, Tanaka K, Goldberg AL . Structure and functions of the 20S and 26S proteasomes. . Annu. Rev. Biochem. . 65 . 801–47 . 1996 . 8811196 . 10.1146/annurev.bi.65.070196.004101 .
• Goff SP . Death by deamination: a novel host restriction system for HIV-1. . Cell . 114 . 3 . 281–3 . 2003 . 12914693 . 10.1016/S0092-8674(03)00602-0 . free .
• Dubiel W, Ferrell K, Pratt G, Rechsteiner M . Subunit 4 of the 26 S protease is a member of a novel eukaryotic ATPase family. . J. Biol. Chem. . 267 . 32 . 22699–702 . 1992 . 10.1016/S0021-9258(18)50002-8 . 1429620 . free .
• Winkelmann DA, Kahan L . Immunochemical accessibility of ribosomal protein S4 in the 30 S ribosome. The interaction of S4 with S5 and S12. . J. Mol. Biol. . 165 . 2 . 357–74 . 1983 . 6188845 . 10.1016/S0022-2836(83)80261-7 .
• Maruyama K, Sugano S . Oligo-capping: a simple method to replace the cap structure of eukaryotic mRNAs with oligoribonucleotides. . Gene . 138 . 1–2 . 171–4 . 1994 . 8125298 . 10.1016/0378-1119(94)90802-8 .
• Seeger M, Ferrell K, Frank R, Dubiel W . HIV-1 tat inhibits the 20 S proteasome and its 11 S regulator-mediated activation . J. Biol. Chem. . 272 . 13 . 8145–8 . 1997 . 9079628 . 10.1074/jbc.272.13.8145 . free .
• Suzuki Y, Yoshitomo-Nakagawa K, Maruyama K, Suyama A, Sugano S . Construction and characterization of a full length-enriched and a 5'-end-enriched cDNA library . Gene . 200 . 1–2 . 149–56 . 1997 . 9373149 . 10.1016/S0378-1119(97)00411-3 .
• Dai RM, Chen E, Longo DL, Gorbea CM, Li CC . Involvement of valosin-containing protein, an ATPase Co-purified with IkappaBalpha and 26 S proteasome, in ubiquitin-proteasome-mediated degradation of IkappaBalpha . J. Biol. Chem. . 273 . 6 . 3562–73 . 1998 . 9452483 . 10.1074/jbc.273.6.3562 . free .
• Madani N, Kabat D . An endogenous inhibitor of human immunodeficiency virus in human lymphocytes is overcome by the viral Vif protein . J. Virol. . 72 . 12 . 10251–5 . 1998 . 9811770 . 110608 . 10.1128/JVI.72.12.10251-10255.1998.
• Simon JH, Gaddis NC, Fouchier RA, Malim MH . Evidence for a newly discovered cellular anti-HIV-1 phenotype . Nat. Med. . 4 . 12 . 1397–400 . 1998 . 9846577 . 10.1038/3987 . 25235070 .
• Gorbea C, Taillandier D, Rechsteiner M . Mapping subunit contacts in the regulatory complex of the 26 S proteasome. S2 and S5b form a tetramer with ATPase subunits S4 and S7 . J. Biol. Chem. . 275 . 2 . 875–82 . 2000 . 10625621 . 10.1074/jbc.275.2.875 . free .
• Zhang Z, Torii N, Furusaka A, Malayaman N, Hu Z, Liang TJ . Structural and functional characterization of interaction between hepatitis B virus X protein and the proteasome complex . J. Biol. Chem. . 275 . 20 . 15157–65 . 2000 . 10748218 . 10.1074/jbc.M910378199 . free .
• Mulder LC, Muesing MA . Degradation of HIV-1 integrase by the N-end rule pathway . J. Biol. Chem. . 275 . 38 . 29749–53 . 2000 . 10893419 . 10.1074/jbc.M004670200 . free .
• Turnell AS, Grand RJ, Gorbea C, Zhang X, Wang W, Mymryk JS, Gallimore PH . Regulation of the 26S proteasome by adenovirus E1A . EMBO J. . 19 . 17 . 4759–73 . 2000 . 10970867 . 302057 . 10.1093/emboj/19.17.4759 .
• Hartmann-Petersen R, Tanaka K, Hendil KB . Quaternary structure of the ATPase complex of human 26S proteasomes determined by chemical cross-linking . Arch. Biochem. Biophys. . 386 . 1 . 89–94 . 2001 . 11361004 . 10.1006/abbi.2000.2178 .
• Matilla A, Gorbea C, Einum DD, Townsend J, Michalik A, van Broeckhoven C, Jensen CC, Murphy KJ, Ptácek LJ, Fu YH . Association of ataxin-7 with the proteasome subunit S4 of the 19S regulatory complex . Hum. Mol. Genet. . 10 . 24 . 2821–31 . 2002 . 11734547 . 10.1093/hmg/10.24.2821 . free .
• Sheehy AM, Gaddis NC, Choi JD, Malim MH . Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein . Nature . 418 . 6898 . 646–50 . 2002 . 12167863 . 10.1038/nature00939 . 2002Natur.418..646S . 4403228 .
• Huang X, Seifert U, Salzmann U, Henklein P, Preissner R, Henke W, Sijts AJ, Kloetzel PM, Dubiel W . The RTP site shared by the HIV-1 Tat protein and the 11S regulator subunit alpha is crucial for their effects on proteasome function including antigen processing . J. Mol. Biol. . 323 . 4 . 771–82 . 2002 . 12419264 . 10.1016/S0022-2836(02)00998-1 .

Notes and References

1. Tanahashi N, Suzuki M, Fujiwara T, Takahashi E, Shimbara N, Chung CH, Tanaka K . Chromosomal localization and immunological analysis of a family of human 26S proteasomal ATPases . Biochem Biophys Res Commun . 243 . 1 . 229–32 . March 1998 . 9473509 . 10.1006/bbrc.1997.7892 .
2. Web site: Entrez Gene: PSMC1 proteasome (prosome, macropain) 26S subunit, ATPase, 1.
3. Gu ZC, Enenkel C . Proteasome assembly . Cellular and Molecular Life Sciences . 71 . 24 . 4729–45 . Dec 2014 . 25107634 . 10.1007/s00018-014-1699-8 . 15661805 . 11113775 .
4. Web site: P62191 - PRS4_HUMAN. Uniprot .
5. Le Tallec B, Barrault MB, Guérois R, Carré T, Peyroche A . Hsm3/S5b participates in the assembly pathway of the 19S regulatory particle of the proteasome . Molecular Cell . 33 . 3 . 389–99 . Feb 2009 . 19217412 . 10.1016/j.molcel.2009.01.010 . free .
6. Funakoshi M, Tomko RJ, Kobayashi H, Hochstrasser M . Multiple assembly chaperones govern biogenesis of the proteasome regulatory particle base . Cell . 137 . 5 . 887–99 . May 2009 . 19446322 . 2718848 . 10.1016/j.cell.2009.04.061 .
7. Park S, Roelofs J, Kim W, Robert J, Schmidt M, Gygi SP, Finley D . Hexameric assembly of the proteasomal ATPases is templated through their C termini . Nature . 459 . 7248 . 866–70 . Jun 2009 . 19412160 . 2722381 . 10.1038/nature08065 . 2009Natur.459..866P .
8. Roelofs J, Park S, Haas W, Tian G, McAllister FE, Huo Y, Lee BH, Zhang F, Shi Y, Gygi SP, Finley D . Chaperone-mediated pathway of proteasome regulatory particle assembly . Nature . 459 . 7248 . 861–5 . Jun 2009 . 19412159 . 2727592 . 10.1038/nature08063 . 2009Natur.459..861R .
9. Saeki Y, Toh-E A, Kudo T, Kawamura H, Tanaka K . Multiple proteasome-interacting proteins assist the assembly of the yeast 19S regulatory particle . Cell . 137 . 5 . 900–13 . May 2009 . 19446323 . 10.1016/j.cell.2009.05.005 . free .
10. Kaneko T, Hamazaki J, Iemura S, Sasaki K, Furuyama K, Natsume T, Tanaka K, Murata S . Assembly pathway of the Mammalian proteasome base subcomplex is mediated by multiple specific chaperones . Cell . 137 . 5 . 914–25 . May 2009 . 19490896 . 10.1016/j.cell.2009.05.008 . free .
11. Rock KL, Gramm C, Rothstein L, Clark K, Stein R, Dick L, Hwang D, Goldberg AL . Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules . Cell . 78 . 5 . 761–71 . Sep 1994 . 8087844 . 10.1016/s0092-8674(94)90462-6. 22262916 .
12. Tian G, Park S, Lee MJ, Huck B, McAllister F, Hill CP, Gygi SP, Finley D . An asymmetric interface between the regulatory and core particles of the proteasome . Nature Structural & Molecular Biology . 18 . 11 . 1259–67 . Nov 2011 . 22037170 . 3210322 . 10.1038/nsmb.2147 .
13. Lander GC, Estrin E, Matyskiela ME, Bashore C, Nogales E, Martin A . Complete subunit architecture of the proteasome regulatory particle . Nature . 482 . 7384 . 186–91 . Feb 2012 . 22237024 . 3285539 . 10.1038/nature10774 . 2012Natur.482..186L .
14. Gillette TG, Kumar B, Thompson D, Slaughter CA, DeMartino GN . Differential roles of the COOH termini of AAA subunits of PA700 (19 S regulator) in asymmetric assembly and activation of the 26 S proteasome . The Journal of Biological Chemistry . 283 . 46 . 31813–31822 . Nov 2008 . 18796432 . 2581596 . 10.1074/jbc.M805935200 . free .
15. Smith DM, Chang SC, Park S, Finley D, Cheng Y, Goldberg AL . Docking of the proteasomal ATPases' carboxyl termini in the 20S proteasome's alpha ring opens the gate for substrate entry . Molecular Cell . 27 . 5 . 731–744 . Sep 2007 . 17803938 . 2083707 . 10.1016/j.molcel.2007.06.033 .
16. Kleiger G, Mayor T . Perilous journey: a tour of the ubiquitin–proteasome system . Trends in Cell Biology . 24 . 6 . 352–9 . Jun 2014 . 24457024 . 4037451 . 10.1016/j.tcb.2013.12.003 .
17. Goldberg AL, Stein R, Adams J . New insights into proteasome function: from archaebacteria to drug development . Chemistry & Biology . 2 . 8 . 503–8 . Aug 1995 . 9383453 . 10.1016/1074-5521(95)90182-5. free .
18. Sulistio YA, Heese K . The Ubiquitin–Proteasome System and Molecular Chaperone Deregulation in Alzheimer's Disease . Molecular Neurobiology . Jan 2015 . 25561438 . 10.1007/s12035-014-9063-4 . 53 . 2 . 905–31. 14103185 .
19. Ortega Z, Lucas JJ . Ubiquitin–proteasome system involvement in Huntington's disease . Frontiers in Molecular Neuroscience . 7 . 77 . 2014 . 25324717 . 4179678 . 10.3389/fnmol.2014.00077 . free .
20. Sandri M, Robbins J . Proteotoxicity: an underappreciated pathology in cardiac disease . Journal of Molecular and Cellular Cardiology . 71 . 3–10 . Jun 2014 . 24380730 . 4011959 . 10.1016/j.yjmcc.2013.12.015 .
21. Drews O, Taegtmeyer H . Targeting the ubiquitin–proteasome system in heart disease: the basis for new therapeutic strategies . Antioxidants & Redox Signaling . 21 . 17 . 2322–43 . Dec 2014 . 25133688 . 4241867 . 10.1089/ars.2013.5823 .
22. Wang ZV, Hill JA . Protein quality control and metabolism: bidirectional control in the heart . Cell Metabolism . 21 . 2 . 215–26 . Feb 2015 . 25651176 . 4317573 . 10.1016/j.cmet.2015.01.016 .
23. Karin M, Delhase M . The I kappa B kinase (IKK) and NF-kappa B: key elements of proinflammatory signalling . Seminars in Immunology . 12 . 1 . 85–98 . Feb 2000 . 10723801 . 10.1006/smim.2000.0210 .
24. Ermolaeva MA, Dakhovnik A, Schumacher B . Quality control mechanisms in cellular and systemic DNA damage responses . Ageing Research Reviews . 23 . Pt A . 3–11 . Jan 2015 . 25560147 . 10.1016/j.arr.2014.12.009 . 4886828.
25. Checler F, da Costa CA, Ancolio K, Chevallier N, Lopez-Perez E, Marambaud P . Role of the proteasome in Alzheimer's disease . Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease . 1502 . 1 . 133–8 . Jul 2000 . 10899438 . 10.1016/s0925-4439(00)00039-9. free .
26. Chung KK, Dawson VL, Dawson TM . The role of the ubiquitin-proteasomal pathway in Parkinson's disease and other neurodegenerative disorders . Trends in Neurosciences . 24 . 11 Suppl . S7–14 . Nov 2001 . 11881748 . 10.1016/s0166-2236(00)01998-6. 2211658 .
27. Ikeda K, Akiyama H, Arai T, Ueno H, Tsuchiya K, Kosaka K . Morphometrical reappraisal of motor neuron system of Pick's disease and amyotrophic lateral sclerosis with dementia . Acta Neuropathologica . 104 . 1 . 21–8 . Jul 2002 . 12070660 . 10.1007/s00401-001-0513-5 . 22396490 .
28. Manaka H, Kato T, Kurita K, Katagiri T, Shikama Y, Kujirai K, Kawanami T, Suzuki Y, Nihei K, Sasaki H . Marked increase in cerebrospinal fluid ubiquitin in Creutzfeldt–Jakob disease . Neuroscience Letters . 139 . 1 . 47–9 . May 1992 . 1328965 . 10.1016/0304-3940(92)90854-z. 28190967 .
29. Mathews KD, Moore SA . Limb-girdle muscular dystrophy . Current Neurology and Neuroscience Reports . 3 . 1 . 78–85 . Jan 2003 . 12507416 . 10.1007/s11910-003-0042-9. 5780576 .
30. Mayer RJ . From neurodegeneration to neurohomeostasis: the role of ubiquitin . Drug News & Perspectives . 16 . 2 . 103–8 . Mar 2003 . 12792671 . 10.1358/dnp.2003.16.2.829327.
31. Calise J, Powell SR . The ubiquitin proteasome system and myocardial ischemia . American Journal of Physiology. Heart and Circulatory Physiology . 304 . 3 . H337–49 . Feb 2013 . 23220331 . 3774499 . 10.1152/ajpheart.00604.2012 .
32. Predmore JM, Wang P, Davis F, Bartolone S, Westfall MV, Dyke DB, Pagani F, Powell SR, Day SM . Ubiquitin proteasome dysfunction in human hypertrophic and dilated cardiomyopathies . Circulation . 121 . 8 . 997–1004 . Mar 2010 . 20159828 . 2857348 . 10.1161/CIRCULATIONAHA.109.904557 .
33. Powell SR . The ubiquitin–proteasome system in cardiac physiology and pathology . American Journal of Physiology. Heart and Circulatory Physiology . 291 . 1 . H1–H19 . Jul 2006 . 16501026 . 10.1152/ajpheart.00062.2006 . 7073263 . https://web.archive.org/web/20190227103826/http://pdfs.semanticscholar.org/79af/c19e3f24828a2debd199d0a09a108dabc7f3.pdf . dead . 2019-02-27 .
34. Adams J . Potential for proteasome inhibition in the treatment of cancer . Drug Discovery Today . 8 . 7 . 307–15 . Apr 2003 . 12654543 . 10.1016/s1359-6446(03)02647-3.
35. Ben-Neriah Y . Regulatory functions of ubiquitination in the immune system . Nature Immunology . 3 . 1 . 20–6 . Jan 2002 . 11753406 . 10.1038/ni0102-20 . 26973319 .
36. Egerer K, Kuckelkorn U, Rudolph PE, Rückert JC, Dörner T, Burmester GR, Kloetzel PM, Feist E . Circulating proteasomes are markers of cell damage and immunologic activity in autoimmune diseases . The Journal of Rheumatology . 29 . 10 . 2045–52 . Oct 2002 . 12375310 .
37. Shi DS, Smith MC, Campbell RA, Zimmerman PW, Franks ZB, Kraemer BF, Machlus KR, Ling J, Kamba P, Schwertz H, Rowley JW, Miles RR, Liu ZJ, Sola-Visner M, Italiano JE, Christensen H, Kahr WH, Li DY, Weyrich AS . Proteasome function is required for platelet production . The Journal of Clinical Investigation . 124 . 9 . 3757–66 . Sep 2014 . 25061876 . 4151230 . 10.1172/JCI75247 .
38. Rual JF, Venkatesan K, Hao T, Hirozane-Kishikawa T, Dricot A, Li N, Berriz GF, Gibbons FD, Dreze M, Ayivi-Guedehoussou N, Klitgord N, Simon C, Boxem M, Milstein S, Rosenberg J, Goldberg DS, Zhang LV, Wong SL, Franklin G, Li S, Albala JS, Lim J, Fraughton C, Llamosas E, Cevik S, Bex C, Lamesch P, Sikorski RS, Vandenhaute J, Zoghbi HY, Smolyar A, Bosak S, Sequerra R, Doucette-Stamm L, Cusick ME, Hill DE, Roth FP, Vidal M . Towards a proteome-scale map of the human protein-protein interaction network . . 437 . 7062 . 1173–8 . October 2005 . 16189514 . 10.1038/nature04209 . 2005Natur.437.1173R . 4427026 .
39. Gorbea C, Taillandier D, Rechsteiner M . Mapping subunit contacts in the regulatory complex of the 26 S proteasome. S2 and S5b form a tetramer with ATPase subunits S4 and S7 . J. Biol. Chem. . 275 . 2 . 875–82 . January 2000 . 10625621 . 10.1074/jbc.275.2.875 . free .
40. Hartmann-Petersen R, Tanaka K, Hendil KB . Quaternary structure of the ATPase complex of human 26S proteasomes determined by chemical cross-linking . Arch. Biochem. Biophys. . 386 . 1 . 89–94 . February 2001 . 11361004 . 10.1006/abbi.2000.2178 .